A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Key Inclusion Criteria:

• Histologically confirmed grade 1-3a FL or MZL

• Previously treated with ≥ 1 line of systemic therapy including anti-CD20 agent. Musthave a documented failure to achieve at least partial response during the mostrecent systemic therapy or documented progressive disease after the most recentsystemic therapy

• Need for systemic therapy for FL or MZL

• Measurable disease by computed tomography or magnetic resonance imaging

• Adequate bone marrow, liver and renal function

Key Exclusion Criteria:

• Transformation to aggressive lymphoma

• Requiring ongoing need for corticosteroid treatment

• Clinically significant cardiovascular disease

• Prior malignancy within the past 2 years

• Active fungal, bacterial, and/or viral infection that requires systemic therapy

• Prior treatment with lenalidomide or drug from same class, if without response (partial or complete) or short remission duration (< 24 months)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.